+1 (202) 780-3397
Commentary - Asian Journal of Biomedical and Pharmaceutical Sciences (2020) Volume 10, Issue 72
Early ambulatory multidrug therapy for SARS-CoV-2 (COVID-19) infection.
SARS-CoV-2 infection (COVID-19) illness involves viral mediated organ damage, cytokine storm, and thrombosis. Once ill, the only method of reducing the risk of hospitalization and death is medical treatment in the ambulatory phase using the same principles for hospitalized patients. Early therapy that has a reasonable chance of success and an acceptable safety profile includes: 1) combination antiviral therapy, 2) corticosteroids, 3) antiplatelet agents/antithrombotics, 4) supportive care including supplemental oxygen, monitoring, and telemedicine. The current rates of hospitalization and death are unacceptably high under the present paradigm of contagion control and watchful waiting for a vaccine.
Author(s): Peter A McCullough1,2,3*